NCT02637284 is a Phase 1 clinical trial of Bepecin in Healthy Volunteers, sponsored by PharmaCotherapia d.o.o..

Who is sponsoring NCT02637284?

NCT02637284 is sponsored by PharmaCotherapia d.o.o..

What drugs are being tested in NCT02637284?

Interventions in NCT02637284: Bepecin, Placebo.

What condition does NCT02637284 study?

NCT02637284 studies Healthy Volunteers.

Is NCT02637284 still recruiting?

NCT02637284 is currently status unknown. Last updated 17 December 2015.

Last reviewed 2015-12-17 · How we verify

NCT02637284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source.

Status unknown Phase 1 Last updated 17 December 2015

What this trial tests

Phase 1 trial testing Bepecin in Healthy Volunteers in 42 participants. Status unknown.

Timeline

1 October 2015

Primary endpoint
1 February 2016

1 March 2016

Quick facts

Lead sponsor	PharmaCotherapia d.o.o.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	42
Start date	1 October 2015
Primary completion	1 February 2016
Estimated completion	1 March 2016
Sites	1 location across Mexico

Drugs / interventions tested

Bepecin — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

PharmaCotherapia d.o.o. — full company profile →

Who can join

Adults 18 to 35, any sex, with Healthy Volunteers. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse events
Time frame: Six months
Any adverse event reported during the study.

Sponsor's own description

Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. · · 2025 · cited 9× · PMID 40005999 · DOI 10.3390/ph18020185
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
Sikiric P, Seiwerth S, Skrtic A, Staresinic M, et al · · 2025 · cited 3× · PMID 40573323 · DOI 10.3390/ph18060928
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, et al · · 2026 · PMID 42198317 · DOI 10.3390/pharmaceutics18050625
Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on "Józwiak et al. Multifunctionality and Possible Medical Application of the
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. · · 2025 · PMID 41155566 · DOI 10.3390/ph18101451

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02637284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PharmaCotherapia d.o.o.
Last refreshed: 17 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02637284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing